biotech · TCR-T Cells · B-ALL · TCRX
TScan Therapeutics
TScan Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 9
- Drugs
- 5
- Patents
- 0
TScan Therapeutics projects
9 ClinicalTrials.gov programs sponsored by TScan Therapeutics.
TScan Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
KSH01 injection
TScan Therapeutics
Solid Tumor
1 trial -
KSH01 injection
TScan Therapeutics
TCR-T Cells
1 trial -
KSV01 Injection
TScan Therapeutics
B-ALL
1 trial -
KSV01 Injection
TScan Therapeutics
Non-Hodgkin Lymphoma
1 trial -
KSX01-TCRT injection
TScan Therapeutics
TCR-T Cells
1 trial -
KXV01 TCR Lentinvivo Injection
TScan Therapeutics
Advanced Solid Tumors
2 trials -
SOC + TSC-100
TScan Therapeutics
AML
1 trial -
TSC-204-A0201
TScan Therapeutics
Head and Neck Cancer
1 trial -
Tcrx T cell
TScan Therapeutics
Gastric Cancer
1 trial
Frequently asked questions
How many clinical projects does TScan Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.